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Summary Patients with small-cell lung cancer who survive more than 2 years have a significantly increased risk (relative risk of 3.6) of
developing a second primary tumour. The cessation of cigarette smoking after successful therapy is associated with a significantly decreased
nsk of a second pnmary tumour.
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The development of a second primary tumour (SPT) in long-term
survivors of small-cell lung cancer (SCLC) emerges as a major
clinical concern requiring intensiVe surVeillance (Johnson et al.
1986: Armnstrong. 1990: Hevne et al. 1992: Richardson et al.
1993). Of these. upper aerodigestive or tobacco-related cancers
predominate (Johnson et al. 1995). The opportunity has been taken
to investigate the finding that cigarette smoking cessation after
successful therapy is associated wvith a decrease in risk for a
second primary tumour (Richardson et al. 1993).
MATERIALS AND METHODS
Patients
From Januarv 1978 to December 1992. 980 consecutix-e patients
with histologically confirmed. previously untreated SCLC were
treated at the National Kinki Central Hospital and Osaka
Prefectural Habikino Hospital Aith combination chemotherapy
with or w-ithout chest radiotherapy.
Definitions
The upper aerodigestive tract includes the epithelial regions of the
head and neck. lunc and oesophagus. Smoking-related cancers
include cancers of the lung. larvmx. oral cavity including phanrnx.
oesophagus. pancreas. bladder. kidney. stomach and uterine cernix
(Blum. 1993). Smokinc histor- in 2-vear cancer-free sunviVors
>-as determined by interviewmig those patients still alive at the
time of manuscript preparation or the relatives of deceased
patients. Smoking cessation was defined as completely stopping
smokinLx within 6 months after initiation of treatment. The period
of the study w-as taken as starting from the first day of
chemotherapy administration. and the date of relapse or second
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pnmarn cancer >-as taken as the day of histological or cytological
documentation of redevelopment of cancer. The appearance of
SCLC more than 2 y-ears after the initiation oftherapy A-as defined
as relapse.
Statistical analysis
For estimation of the expected x-alues of second cancer desvelop-
ment. the period of risk began 2 years after initiation of treatment
for SCLC and ended with the date of death. date of last follow-up
or date of diagnosis of a second cancer. w-hichever occurred first.
Age. sex. and period-specific rates for cancer incidence x-ithin the
period 196-3-92 were applied to the appropriate person-years of
obsernation (Osaka Prefectural Department of Environment and
Public Health. 1993: Osaka Prefectural Department of Health.
1995). The cancer incidence data for 1992 A-ere applied to the
person-years from 1992 to 1995. Statistical methods for risk esti-
mation Nvere based on the assumption that the obserned number of
second cancers follow-ed a Poisson distribution (Boice et al. 1991).
To calculate excess risks per 10 000 patients per y ear in subgroups
w-ith sianificant relatix-e risks. the expected number of cases w-as
subtracted from the number observed. The difference Aas divided
by person-years ofobservation. then multiplied by IO-. The risk of
a SPT with a specific exposure (e.g. smoking and treatment) x-as
estimated by comparing the patients without the specific
exposure. using Poisson regression methods (SAS Institute. 1989)
adjusting for sex. age (> 65 vs < 65 nears old). performance status
(PS) (0-1 Xs 2-4). etoposide. radiotherapy and cumulatiVe
smoking amount before diacnosis of SCLC (> 45 pack-year vs
< 45 pack-years ).
RESULTS
Of the 980 patients of SCLC treated in the two hospitals. 70 (7%5
x-ere alive and free of cancer at least 2 vears after the initiation of
treatment. The median survival time of these 70 patients >-as 9.0
years from initiation of treatment for SCLC. Five- and 10-vear
survival rates A-ere 83=/e and 43% respectixely. Ten patients wxere
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Table 1 Charactenstics of 15 pabents with a second primary tumour
Age at Cancer-free
Patient diagnosis Disease Initial site interval Continued Chest Second primary tumour/ Third primary tumour/
no. (years) Sex extent of the lung (years) smoking radiotherapy histological type histological type
1 60 M Limited RUL 2.2 Yes Yes Oesophagus/squamous Larynx/
squamous
2 71 M Limited LLL 2.3 No No Stomach/adenocarcinoma
3 70 M Limited LLL (B10) 2 3 Unknown No Lung (RUL)/squamous
4 77 F Limited RUL 3.5 Yes Yes Lung (LLL)/squamous
5 63 M Limited RUL 3.8 No Yes Oesophagus/squamous
6 57 F Limited RLL 4.7 Yes Yes Larynx/squamous
7 68 F Limited LUL 4.9 Yes No Stomach/adenocarcinoma Gall bladder/
adenocarcinoma
8 60 M Limited RUL 5.3 Yes Yes Prostate/adenocarcinoma
9 72 M Limited RLL 5.5 Yes Yes Lung (RML)/adenocarcinoma
10 53 M Limited RUL 6.4 No Yes Gallbladder/adenocarcinoma
11 56 M Limited LLL 6.6 Yes Yes Bladder/transitional cell ca
12 57 M Limited RLL 6.6 Yes Yes Acute myelogenous leukaemia
13 69 F Limited RLL 7.0 Yes Yes Lung (RLL.B6)/squamous
14 68 F Limited RUL 7.4 Yes No Larynx/squamous
15 62 F Limited LUL 8.1 Yes Yes Lung (RLL)/squamous
RUL. right upper lobe: RML. right middle lobe: RLL. right lower lobe: LUL. left upper lobe: LLL. left lower lobe.
alixe more than 10 years after initiation of therapy. The 2-year
survixor population xxas made up of 12%7c (64 out of 525) wxith
limited-stage and 1%c (6 out of 455 x with extensive-stage disease.
The median follow--up from initiation of therapy was 6.7 vears
(ranae'.1-15.1 vears).
Fifteen of the 70 disease-free survivors dexeloped one or more
SPTs 2.2-8.1 years (median. 6.1 years) after beginning therapy for
SCLC. Details ofthese patients are shown in Table 1. Five patients
(cases 3. 4. 9. 13 and 15) developed a second primary lung cancer
(other than SCLC) (four squamous. one adenocarcinoma). of
which four occurred in different lobes from the original SCLC.
Four of the patients receixved radiotherapy. Two second primarx
lung cancers developed outside the radiation field (cases 4 and 9).
The other malignancies consisted of carcinomas of the stomach.
oesophagus. larynx. prostate. gallbladder and bladder. and acute
myelogenous leukaemia.
Of the 70 patients. nine relapsed with SCLC. These relapses
occurred 2.0-8.5 years after the initiation of SCLC. Twentx -fixve
patients have died: five from recurrent SCLC. 11 from a SPT. The
other causes ofdeaths unrelated to cancer were pulmonary disease
(n = 3). cardiac disease (n = 2). cerebrovascular disease (n = 1).
neurological disease (dementia after whole brain irradiation for
SCLC) (n = 1) and unknown (n=).
Table 2 shows the relative and absolute risks ofSPT after initia-
tion of therapy for SCLC. The risk for development of any SPT
increased significantly by 3.6 [95%7c confidence interval (CI)
2.0-5.9]. This oxerall increase in risk was mainlv due to the 7.0-
fold increase in lung cancer other than SCLC (95c7% CI 2.3-16.4). a
41.1-fold increase in carcinoma of the larvnx (95%7c CI 4.5-144.4)
and a 15.6-fold increase in carcinoma of the oesophagus (95%7c
CI 1.7-55.5). The relati-e risk of all upper aerodigestixe cancers
(nine patients) was 9.3 (95c CI 4.3-17.7). When smoking-related
cancers (12 patients) are combined. the relatixe risk was 5.2 (95c%
CI 2.7-9.1).
Smoking status after the initial primary tumour was axailable
for all but one patient (case 3 in Table 1). Smoking status was
obtained directly from 44 patients (63%). from relatives for 20
(29%) and from the patients' medical records for five (77c). There
has been no SPT among the fixve nexver smokers. After initiating
therapy for SCLC. 33 patients (49%/c) continued to smoke and 31
patients (48%7c) stopped smoking (Table 3). Of the patients xho
continued to smoke. 11 (33%7c) dexeloped a SPT. Ofthe 31 patients
x ho stopped smoking after therapy. only three (10%c) had a subse-
quent SPT (cancer of the stomach. oesophagus and gallbladder
respectixely. see Table 1). Among those wxho continued to smoke.
the risk for a SPIT was significantly increased (5.4 times: 95%7c
CI 2.7-9.7). relatixe to the aeneral population. In contrast. those
wxho stopped smoking showxed only a 1.6-fold increase (95%7c
CI 0.3-4.6). which wxas not significantlx different from the lexel
in the general population. The relative risk for non-SCLC was
sianificantlv increased 12.8-fold (95c/c CI 3.4-32.8) in continuing
smokers. No second non-SCLCs have been found amona those
x ho stopped smoking.
We assessed the relationship betxxeen continued smokin2 habits
and the risk of a SPT. adjusted for sex. PS. age. etoposide treat-
ment. radiotherapy and cumulatixe smoking history. The results
are showxn in Table 4. The 33 patients who continued to smoke had
a significantly increased risk of a SPF (4.3. 95%7c CI 1.1-15.9.
P=0.03). The other factors such as sex. PS. age. cumulative
smokine amount. use ofthe anticancer drug etoposide or radiation
had no effect on the dexelopment of a SPI. We assessed the inter-
action between smoking habits and radiotherapy on the risk of a
SPT. Relative to the risk ofSPT in patients without previous radio-
therapy wxho stopped smokingy. the risk is 0.92 in patients without
radiotherapy wxho continued smoking. 0.37 in patients with radio-
therapy who stopped smoking. and 2.33 in patients with radio-
therapy who continued smoking. The risk of current smoking in
patients with previous radiotherapy is 6.30 relatixve to those xith
radiotherapy wxho stopped smoking. although this interaction is not
statistically significant (P = 0.24). possibly because of the small
number ofpatients.
DISCUSSION
In our study. 15 patients out of 70 long-term surxixors of SCLC
had a SPT. The relatixe risk for any SPF compared xxith the
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Table 2 Risk of a second primary tumour in patients surviving 2 or more years free of small-cell lung cancer
Tumour type Observed Expected O/E 95% Cl Absolute risk
All cancers 15 4.19 3.6 2.0-5.9 33.4
Lung 5 0.71 7.0 2.3-16.4 13.2
Larynx 2 0.05 41.1 4.5-144.4 6.0
Oesophagus 2 0.13 15.6 1.7-55.5 5.8
Stomach 2 0.98 2.0 0.2-7.4 3.1
Bladder 1 0.19 5.1 0.1-29.3 2.5
Prostate 1 0.10 9.8 0.1-55.6 2.8
Acute myelogenous 1 0.05 21.6 0.3-111.3 2.9
leukaemia
Gallbladder 1 0.13 7.7 0.1-42.8 2.7
0. observed: E. expected: Cl. confidence interval.
Table 3 Risk of a second primary tumor in different time intervals for patients surviving 2 or more years free of cancer by intercurrent smoking status
Pafients who continued smoking (33) Patients who stopped smoking (31)
0 O/E 95% Cl Absolute risk 0 O/E 95% Cl Absolute nsk
Second primary tumours
Total 11 5.4 2.7-9.6 56.2 3 1.6 0.3-4.6 8.9
2-3 years 2 2.9 0.3-10.5 21.7 2 2.8 0.3-9.9 24.2
4-5 years 4 6.9 1.9-17.8 73.4
6-7 years 4 10.1 2.7-25.8 121.1 1 2.6 0.0-14.6 28.0
8-9 years 1 4.8 0.1-26.5 58.3
Upper aerodigestive cancers
Total 7 14.8 5.9-30.6 41.0 1 2.2 0.0-12.1 4.4
2-3 years 2 13.4 1.5-48.4 30.6 1 5.8 0.1-32.1 15.7
4-5 years 2 15.3 1.7-55.4 40.1
6-7 years 2 21.5 2.4-77.5 64.1
8-9 years 1 19.2 0.3-106.6 69.9
Smoking-related cancers
Total 9a 8.0 3.6-15.1 49.4 2a 1.9 0.2-6.7 7.5
2-3 years 2 5.4 0.6-19.4 26.9 2 4.8 0.5-17.4 30.1
4-5 years 3 9.5 1.9-27.8 57.5
6-7 years 3 13.7 2.7-40.1 93.5
8-9 years 1 8.4 0.1-46.9 65.0
0. observed; E. expected, Cl. confidence interval. aOne smoking-related cancer is not shown as the smoking status was not available (case 3 in Table 1).
general population was significantly increased s%ith a relative risk
of 3.6 (95%c CI 2.0-5.9). The risk was substantially higher for
tumours located in the upper aerodigestive tract and for the total
related to smoking. Richardson et al (1993) also report that a risk
for any SPT is 4.4 (95% Cl 2.5-7.2).
Smokinc history after treatment of SCLC influenced the risk of
development of a SPT. The 33 patients who continued to smoke
had a significantly increased risk for a SPF (4.3. 95%c CI 1.1-15.9.
P = 0.03) compared with those who stopped smoking. Richardson
et al ( 1993) reported that the patients who continued to smoke had
a threefold increased risk for a second primary luna cancer
compared w-ith the patients who stopped smoking. However. w-e
could not calculate the risk of second primarv lung cancer because
no second primary non-SCLC has been found in those who
stopped smoking in our patients. There appeared to be an inter-
action between smoking and chest irradiation. the risk of current
smokingr combined with previous radiotherapy being 6.30 relative
to those with radiotherapy who stopped smokingy. although this
interaction is not statistically significant (P = 0.24). perhaps
because of the small number of patients. This suggest that.
althouah irradiation itself is beneficial for lona-term survivors of
SCLC. current smokina after previous irradiation is harmrful to
these patients. Recently. Tucker et al (1997) reported a similar
interaction for the risk of a second lung, cancer betmeen smoking,
after treatment and previous chest irradiation. although. as in the
present study. the interaction w-as not statistically significant.
In conclusion. these data indicate that patients swith SCLC who
surnive cancer-free for more than ' -ears have a significantly
increased risk of developing a SPT. and that the cessation of ciga-
rette smoking, after successful therapy is associated with a decreased
risk for a SPT. These data warrant cessation of smokina amonc
patients with SCLC and the importance for developing efficient
proggrammes to support patients attempting to give up smoking.
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Table 4 Relative risk of a second primary tumour adjusted for intercurrent smoking, sex, age,
performance status, etoposKde treatnent, radiotherapy and cumulative smoking amount are assessed
Risk factor Relabve risk (95% Cl) P-value
Intercurrentsmoking Yes/no 4.3 (1.1-15.9) 0.03
Sex Female/male 1.9 (0.5-6.7) 0.32
Age (years) 65 S/< 65 0.9 (0.3-3.2) 0.89
Performance status 2-4/0-1 0.4 (0.0-3.4) 0.39
Etoposide Yes/No 1.6 (0.5-5.1) 0.41
Radiotherapy Yes/No 1.6 (0.4-6.1) 0.50
Cumulative smoking 45 :/< 45 0.9 (0.2-3.3) 0.82
amount (pack-years)
Cl. confidence interval.
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